Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.09M | -1.93M | -1.48M | -1.53M | -1.64M |
| Total Depreciation and Amortization | 115.80K | 107.30K | 72.50K | 74.80K | 123.20K |
| Total Amortization of Deferred Charges | -- | -- | 45.30K | 46.70K | -- |
| Total Other Non-Cash Items | 97.00K | 90.00K | -89.50K | -92.30K | 21.00K |
| Change in Net Operating Assets | 14.80K | 13.70K | -65.00K | -67.10K | -29.60K |
| Cash from Operations | -1.86M | -1.72M | -1.52M | -1.57M | -1.52M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 8.00K | 8.20K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | -63.50K |
| Cash from Investing | -- | -- | 8.00K | 8.20K | -63.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -36.50K | -36.50K | -42.00K | -42.00K | -41.50K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.50K | -31.50K | 446.00K | 446.00K | 1.13M |
| Cash from Financing | -77.20K | -71.60K | 430.70K | 444.10K | 1.17M |
| Foreign Exchange rate Adjustments | 600.00 | 500.00 | -2.10K | -2.20K | -- |
| Miscellaneous Cash Flow Adjustments | -600.00 | -500.00 | 500.00 | 600.00 | -500.00 |
| Net Change in Cash | -1.94M | -1.79M | -1.08M | -1.12M | -417.10K |